FDA Committee Votes Against Bayer’s Cipro Inhalation Powder

Drug Industry Daily
A A
An FDA advisory committee voted Thursday to not recommend two regimens for Bayer’s inhalation-powder formulation of ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis, citing inconsistent data from clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily